Drug Trial Radar · NCT07187375
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
7
Actual
Start
Sep 30, 2025
Primary completion
Sep 6, 2029
Study completion Oct 4, 2029
Sponsor
- Lead sponsor
- Neurocrine Switzerland GmbHNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Sep 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 23 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).
Conditions
- Congenital Adrenal Hyperplasia
Interventions
CrinecerfontDrug
Oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Concentration of CrinecerfontTime frame: Days 7 and 15
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Berlin, Germany
Neurocrine Clinical Site
Düsseldorf, Germany
Neurocrine Clinical Site
Heidelberg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.